Description: PRASCEND® (pergolide tablets) is the #1 treatment approved by the FDA for Pituitary Pars Intermedia Dysfunction (PPID).4Proven to improve clinical signs such as delayed shedding, muscle wasting, and abnormal sweating. PRASCEND helps horses with PPID have healthier, more comfortable lives. PRASCEND is a rectangular light red colored, half-scored tablet containing 1 mg pergolide, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only.1Only treatment for PPID (equine Cushing's disease) in horses approved by the FDA1Improves clinical signs within 3 months, sustained through 6 months13 out of 4 horses considered treatment successes in clinical trials1Hypertrichosis (delayed shedding) improved in 89% of treated horses within 6 months1Incorporating PRASCEND tablets into a PPID management protocol has been shown to reduce clinical signs of the disease and enhance horses' overall quality of life. Clinical research and real-world evidence show that horses treated with PRASCEND:Are supported with the only therapy for PPID approved by the FDA1Showed improved clinical signs within 3 months, with continued improvement at 6 months1Experienced significant improvement in delayed shedding (89%), muscle wasting, abnormal fat distribution, and abnormal sweating within 6 months1Achieved a 76.1% overall treatment success rate based on clinical signs and endocrine testingSustained improvement and owner satisfaction in a long-term study, with 87% of owners reporting they would choose PRASCEND again for another PPID horse2Benefit from consistent, reliable dosing and potency, unlike compounded pergolide products, which have been shown to lose effectiveness rapidly3References:
1. Boehringer Ingelheim Vetmedica, Inc.PRASCEND (pergolide mesylate) Tablets for Horses: Freedom of Information Summary. NADA 141-331. US Food and Drug Administration. Sept 7, 2011.
2. Schott HC, Strachota JR, Marteniuk JV, Refsal KR. Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide.J Vet Intern Med.2025;39:e70109. doi:10.1111⁄jvim.70109
3. Stanley SD, DiMaio Knych H. Comparison of pharmaceutical equivalence for compounded preparations of pergolide mesylate. In:Proc 56th Annu Conv Am Assoc Equine Pract.2010:274-276.
4. Boehringer Ingelheim. Data Supporting PRASCEND as #1 treatment for PPID. Supporting Document VV-55869. November 2025.
Product sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer.
For: Horses
Brand Name: Prascend
Drug Class: Dopamine receptor agonist
Product Strength & Size: Prascend Tablets contain 1 mg of pergolide in eachtablet- packaged 10 tablets per blister and 60 or 160 tablets per carton. Please ensure the selected product and package size are appropriate for your pet, as recommended by your veterinarian. For current availability, please refer to the product selection above.
Manufacturer: Boehringer Ingelheim
